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ABSTRACT
A dual precipitation method using dextran sulfate (MW
15,000) and magnesium chloride for the subfractionation of human
serum high-density lipoprotein (HDL) was evaluated and applied to
the study of lipid abnormalities in renal patients. The dual
precipitation procedure used in this study measured total HDL and
its subfractions with accuracy and precision comparable with the
widely used phosphotungstic acid-Mg+2 and ultracentrifugation
methods and yielded the correlation coefficients of 0.994 and
0.988 for total HDL and HDL3, respectively.
The patients' study compared different renal
replacement therapy of end-stage chronic renal failure patients
on serum lipid, lipoprotein and apolipoprotein concentrations
with focus on the cholesterol content in HDL subfractions. The
study group consisted of 77 Chinese chronic uraemic patients
treated with hemodialysis (HD), continuous ambulatory peritoneal
dialysis (CAPD) and renal transplantation (PRT). Mean serum
concentrations of cholesterol, HDL- and HDL2-cholesterol were
significantly higher in females when compared to males for
control subjects. These sex-related differences were not observed
in patients treated with hemodialysis. Mean serum concentrations
of cholesterol, HDL- and HDL2-cholesterol, apolipoprotein A-I
(Apo A-I) and apolipoprotein B (Apo B) were all significantly
reduced in both male and female patients of the HD group. The
decrease in HDL-cholesterol was accounted for by a decrease in
both HDL2-cholesterol and HDL3-cholesterol. In the PRT group,
mean serum triglyceride, cholesterol and Apo B concentrations
were significantly higher than in either the control subjects or
HD patients for both sexes. In comparison with controls, no
significant abnormalities in Apo A-I, HDL- and HDL2-cholesterol
values could be found. The CAPD patients had the highest
triglyceride and Apo B, and the lowest HDL- and HDL2-cholesterol
mean serum concentrations for both sexes when compared with the
control subjects and patients treated with HD or PRT. Regarding
the mechanism of the elevation of triglycerides during these
dialysis treatments and renal transplantation, these findings
indicate disturbance of HDL metabolism, but the mechanisms
underlying the relationship between these changes and the
development of accelerated atherosclerosis remain uncertain.
Further studies are clearly needed to elucidate the
interrelationship between lipoprotein classes, especially the HDL
subfractions and the lipolytic enzyme activities in uraemic
patients under renal replacement therapy.
CHAPTER 1
INTRODUCTION
This chapter attempts to review current knowledge and
concepts about high-density lipoprotein (HDL) and its
subfractions. It opens with a brief description of the
epidemiological and clinical aspects of HDL with special
emphasis on the relationships to coronary heart disease and renal
disorders. It then proceeds to describe the changing concepts
about the metabolism of HDL and its subtractions in health and
disease. Finally, it presents the currently available techniques
for the isolation and quantitation of HDL subtractions. The aim
of the present study is given in the last section.
1.1 Epidemiological and clinical aspects of high-density
lipoproteins
1.1.1 High-density lipoproteins and coronary heart disease
As early as 1951, Barr and co-workers [1] reported an
association of lower concentration of plasma alpha- or high-
density lipoprotein (HDL) with coronary heart disease (CHD). This
was subsequently confirmed in several major studies. HDL was
curiously neglected for some 25 years until one study group [2]
reemphasized the inverse relationship between serum HDL
concentration and CHD in almost 7,000 subjects from five
separate epidemiologic studies (Albany; Framingham; Evans County;
Honolulu; and San Francisco), A spate of confirmatory reports
soon followed [3, 4, 5].
High-density lipoproteins have been shown to consist of
the major subtractions HDL2 and HDL. In 1981, Miller [6]
reported that lower plasma HDL2 concentrations were associated
with increased CHD severity whereas lower HDL concentrations
were not. He suggested that the link between HDL metabolism and
atherosclerosis appeared to be more closely related to HDL2
metabolism than to total HDL concentrations. At about the same
time, Brook et al. [7] found that both plasma HDL2 and HDL
concentrations were significantly reduced in CHD patients when
compared with matched control subjects even though their plasma
very-low-density lipoprotein (VLDL) and low-density lipoprotein
(LDL) concentrations were similar.
A dramatic rise in the interest for the analysis of HDL
subfractions has occurred in the past 10 years because of the
emerging evidence for a different role of the two major
subfractions. In 1976, Index Medicus listed 85 articles under
the heading of Lipoprotein, HDL in which only 3 articles had
included the subfractions of HDL in their titles. By 1986,
numbers had increased to a total of 272 under two separate
sections: Lipoprotein, HDL and Lipoprotein, HDL- Cholesterol and
the number of using subfractions increased to 42.
1.1.2 Accelerated atherosclerosis in uraemic patients
Lindner et al. [8] were among the first to show that
cardiovascular disease is the main cause of death in chronic
hemodialysis patients. The incidence of this disease pattern is
several times greater for uraemic and dialysis patients than for
hypertensives with normal renal function and patients with type
Ila hyperlipoproteinaemia. Lipid abnormalities have been reported
in patients treated with continuous ambulatory peritoneal
dialysis [9, 10,11],
Atherosclerosis has been suggested to be accelerated
not only in patients with chronic renal failure (CRF) being
treated with hemodialysis and peritoneal dialysis but also
commonly in patients carrying a kidney graft [12]. Ibels and co¬
workers [13] studied the nature and causes of hyperlipidaemia
in uraemia, maintenance dialysis and renal transplantation and
showed that hypertriglyceridaemia and a decrease in HDL, together
with other risk factors such as hypertension, hyperuricaemia,
glucose intolerance, phosphate retention with vascular
calcification, and smoking, play an important role in the
accelerated development of atherosclerosis in the uraemic
patients treated with hemodialysis and transplantation. Various
authors agreed with this [14, 15], although whether
atherosclerosis is actually accelerated in these patients is
still controversial [16, 17]. However, a recent study suggests
that an early graft may prevent the development of accelerated
atheromatosis [18].
Although there are extensive data concerning the lipids and
lipoproteins abnormalities in patients with chronic renal failure
receiving hemodialysis, peritoneal dialysis and kidney
transplantation, little information is avaliable on the
relationship between serum HDL subtractions and uraemia [19, 20],
and there is paucity of data for patients treated with continuous
ambulatory peritoneal dialysis.
1.2 Metabolism of HDL and HDL subfractions
The identificaton of HDL concentration as a negative
risk factor for coronary heart disease has recently stimulated
interest in the regulation of plasma HDL concentrations. Thus an
understanding of HDL synthesis and metabolism has now assumed an
increased importance. It is well known that chylomicrons, VLDL
and HDL have a metabolic interrelationship [21]. The liver
synthesizes and secretes primarily VLDL and HDL. The
triglycerides of chylomicrons and VLDL are removed by lipoprotein
lipase (LPL) from the circulation; degradation of VLDL yields
intermediate-density lipoproteins (IDL); IDL remnants accumulate
in patients with type III hyperlipoproteinaemia and are highly
atherogenic. The final product of VLDL degradation is LDL, the
major carrier of cholesterol in plasma and the lipoprotein most
closely linked with atherogenesis. Levy and Rifkind [22]
indicated that while 60-75% of cholesterol is carried in the LDL
fraction, 20-25% is associated with HDL. The latter is heavier
since 50% is protein. However, mature spherical HDL particles are
not secreted directly from either intestine or liver but derived
from discoid- shaped precursors consisting of apolipoproteins
(Apo A-I and Apo A-II, 90%; Apo C's constitute approximately 5%),
lecithin, and free cholesterol. The discoid- sphere
transformation involves the action of lecithin- cholesterol
acyltransferase (LCAT) which is activated by Apo A—I and which
also esterifies cholesterol. HDL may also originate from
triglyceride-rich VLDL and chlyomicrons, requiring lipolysis by
LPL (activated by Apo C-II). It has a half life of four days. HDL
facilitates cholesterol transport from the cell to the liver and
may decrease the rate of entrance of LDL-cholesterol into cells
and increase the rate of cellular release of cholesterol. HDL may
also scavenge lipolytic debris of chylomicrons and VLDL. HDL
differs from atherogenic lipoproteins because it contains no Apo
B, which gives lipoproteins a noxious capacity to bind with
negatively charged glycosamino-glycans located in the arterial
intima. Thus the possible differences observed in their
composition may be connected with the activity of LPL and LCAT.
The component of the major plasma lipoproteins are summarized in
Table 1.
1.2.1 Roles of HDLoand HDLo in lipoprotein metabolism
HDL is a heterogeneous entity of lipoprotein
particles, including at least two separate subfractions, HDL2 and
HDL [25]. Shore [26] has made a detailed analysis of the N- and
C-terminal amino acid residues in the HDL2 and HDL subfractions.
In both subfractions, peptide units of approximately molecular
weights of 95,000 were found with aspartic acid as N-terminal and
threonine as C-terminal. From molecular weight determination and
in view of identity in amino acid composition, it was estimated
that HDL2 contains two of the peptide chains present in HDL.
This evidence was reassessed by the introduction of the concept
of apolipoproteins in subsequent studies [27, 28]. Previous
reports indicated that the variations in total HDL mainly reflect
Table 1
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changes in HDL2 while HDL remains relatively stable [29]. This
suggests that the two HDL subtractions have different metabolic
pathways. Indeed, a precursor product relationship has recently
been demonstrated between HDL and HDL2 during the degradation of
triglyceride-rich lipoproteins by lipoprotein lipase (LPL) in
vitro [30], and in vivo [313. The LPL activity of vascular
endothelium is in fact one of the factors which regulates the
plasma level of HDL [32]. Tall [33] suggested that the clearance
of chylomicrons and VLDL from the circulation by the action of
LPL results in the release of redundant components from their
surface and that these fragments may fuse with circulating HDL
to produce particles resembling HDL2. Studies suggest that these
events in vitro also take place in vivo in man. HDL is also
believed to accept the phospholipid and Apo-C librated from VLDL,
together with some free cholesterol. By this process it is
converted into the lower density subtraction HDL2 [34]. The
results of BaggioTs study [35] show that in the post-prandial
phase, the HDL2 and HDL subtractions present significant
variation, but the HDL2, which are about one-quarter of the HDL,
show greater fluctuation. During the post-prandial phase,
moreover the HDL2 increase in the female, compared to the male,
is more evident as already demonstrated in fasting plasma. It may
be hypothesized that the higher increase in HDL2 in the females
is due to a more pronounced capacity to remove triglyceride-rich
particles. This may be important because it has recently been
suggested that the putative protection against atherosclerosis in
females may be related to their higher HDL2 subtractions [36].
1-2-2 Factors affecting the level of plasma HDL subfractions
Many factors are known to affect plasma HDL [37] and in
particular, HDL2 concentrations. Among these are: diet, alcohol
consumption, drugs, and physical activity in addition to genetic
factors [38, 39, 40]. Several of these are linked to fluctuations
of the activity of lipolytic enzymes, adipose tissue lipoprotein
lipase, andor lipoprotein lipase of hepatic origin. One
explanation of these interrelationship might be that during
lipolysis of triglyceride-rich lipoproteins (TGRLP), surface
components of chylomicrons and VLDL are transferred to HDL2 as
observed in vivo [41]. Other authors, in contrast, believe that
LCAT is the main enzyme that converts HDL to HDL2 [42].
1.3 Laboratory methods for the measurement of HDL subfractions
Lipoproteins can be considered as a continuous spectrum
of lipid: protein associated with hydrated densities ranging
from less than 1 to approximately 1.25 gmL. A stepwise flotation
at increasing densities may lead to homogeneous fractionations.
Very-low-density lipoproteins (VLDL, d= 0.95-1.006 gmL) have
been separated into five subfractions by stepwise flotation [43],
low-density lipoproteins (LDL, d= 1.006-1.063 gmL) into three to
five subfractions [44] and high-density lipoproteins (HDL, d=
1.063-1.21 gmL) into three subfractions [45]. HDL has two major
subfractions HDL2 and HDL with hydrated densities of 1.063-1.125
and 1.125-1.210 gmL, respectively. However, reports on the
number of HDL subfractions and their hydrated densities are not
all consistent. Nevertheless, several methods have been described
recently for determination of HDL2 and HDL2 in epidemiological
and clinical studies. In all these methods, ultracentrifugations
are performed at d= 1.125 gmL. In order to find a simple and
reliable method for the purpose of the study of HDL subfractions,
a brief review of the presently available methodologies is
essential. A number of procedures that are presently available
for the fractionation of serum lipoproteins can also be applied
for the subfractionation of HDL. These include, rate zonal
ultracentrifugation, preparative ultracentrifugation, analytical
ultracentrifugation, density gradient ultracentrifugation,
gradient gel electrophoresis, high performance liquid
chromatography, isoelectric focusing, and polyanion-divalent
cation precipitation.
1.3-1 Rate zonal ultracentrifugation
This method was first applied for the separation of
lipoproteins by Wilcox and Heimberg [46] and has been modified by
others for subfractionation of HDL [471. The particular advantage
of rate zonal ultracentrifugation lies in the fact that
lipoprotein separation becomes immediately evident from
densitometric evaluation of the eluate, allowing one to cut any
number of fractions at any peak maximum, minimum and shoulder.
Plasma samples ranging from 0.5-1 mL to as large as up to 50 mL
have been successfully separated.
1-3.2 Preparative ultracentrifugation
The separation of HDL subtractions in the preparative
ultracentrifugation is based on the existence of regions of
maximal and minimal concentrations at certain density intervals,
being 1.063-1.125 gmL and 1.125-1.210 gmL for HDL2 and HDL,
respectively [48]. Following the ultracentrifugation, the top
fraction containing the concentrated lower density lipoproteins
is removed by aspiration or tube slicing. The desired HDL
subtraction is obtained as the bottom fraction. Isolation and
purification of lipoprotein density subtractions in the
preparative ultracentrifugation using fixed-angle rotors requires
long exposure of these macromolecules to high salt concentrations
and high gravity fields. This procedure has been shown to
interfere with lipid-protein binding [49] and may affect the
subsequent determination of their constituents.
1.3.3 Analytical ultracentrifugation
Measurement of HDL subfractions by analytical
ultracentrifugation requires prior separation of the total HDL
fraction from other serum lipoproteins [50]. Analysis is
performed in an analytical ultracentrifuge equipped with a
diagonal wire cylindrical lens. The optical system actually
provides a measure of the refractive index gradient (dndx) as a
function of distance (x) from the centre of rotation. This
technique generates a Tschlieren curve' which describes the
distribution of lipoproteins according to their high density
flotation (F) and low to very low density flotation (S°f) rates,
from which concentrations of HDL subfractions are calculated with
the use of areas under the curve for arbitrary specified
flotation intervals. HDL2 mass is approximately as the sum of
flotation interval F|2q, 3-5-9.0 and HDL mass is approximated
as the sum of F-j 20, 0-3.5.
Uncertainties may be introduced into the measurement of
HDL subfractions by analytical ultracentrifugation by: (1)
degradation of the lipoproteins during the preparative and
analytic phases of ultracentrifugation. (2) potential differences
in the specific refractive increment of HDL subfractions. (3) an
opposing contribution to the lipoprotein 'schlieren pattern1 due
to the sedimentation of a small amount of residual albumin in the
d 1.20 grnL fraction. Greater accuracy and resolution can only
be achieved with the aid of a computer for reading the Tschlieren
patterns1 [51].
1.3.4 Density gradient ultracentrifugation
Chapman et al. [52] described a density gradient
ultracentrifugation procedure for rapid and reproducible
isolation of HDL subfractions from human serum. A step gradient
is constructed from NaClKBr solution varying in density from
1.006 to 1.24 gmL and from the serum sample adjusted to d= 1.21
gmL. Separation is achieved after a single spin for some 56 x
107 g min at 15°C in a swinging bucket rotor. Densitometric
scanning of gradients revealed a lipoprotein mass profile
distinguished by the absorption maxima which fell within the
hydrated density ranges of HDL2 (1.066-1.100 gmL) and HDL
(1.100-1.153 gmL). Fractionation of gradients in the band
distribution followed by chemical, physical, and immunochemical
analyses, confirming their identities as HDL2 and HDL. This
procedure reduces the number of separate ultracentrifugation
steps, and allows the processing of six separate serum samples at
one time in a swinging bucket rotor.
1-3-5 Gradient gel electrophoresis
Gradient gel electrophoresis in conjunction with
automated densitometry was applied to the identification and
estimation of HDL subfractions in the uitracentrifugal d 1.200
fraction of serum sample [53]- This method is based upon the fact
that the migration distance of each globulin protein of the HDL
subfractions on a continuous pore-gradient is inversely
proportional to the logarithm of their diameters, and that a
calibration of the migration distance in terms of Stokes1
diameter is possible. The Stokes1 diameter of each protein was
calculated from its diffusion coefficient according to the
Stokes-Einstein relationship [54]. Quantitation of HDL
subfractions by gradient gel electrophoresis is complicated by
the fact that these subfractions are only partly resolved under
current conditions of electrophoresis and gel gradient [55].
1.3.6 High performance liquid chromatography (HPLC)
In 1980, Okazaki and Hara [56] succeeded in the
separation of human serum HDL into subfractions by high
performance liquid chromatography using a gel permeation column.
The separation is based on the difference in particle size of the
HDL subfractions. The quantitation of cholesterol contents of HDL
subfpactions could be performed with only 10-20 uL of serum in
less than 50 minutes by measuring the absorbance at 550 nm after
passing the mixed eluate and enzyme solution through an on-line
reactor system of a high speed chemical derivatization liquid
chrmatography. Two of the advantages of this technique are that
no decomposition of lipoproteins is detectable and the
reproducibility of the separation is good.
1.3.7 Isoelectric focusing (1EF)
Isoelectric focusing has been used to demonstrate the
heterogenecity of high-density lipoprotein [57]. The focusing
technique basically involves applying an electric field to the
lipoproteins contained in a pH gradient (pH increasing from anode
to cathode). For a given pH gradient and electric field, the
result should be an equilibrium state dependent only upon the
diffusional and charge properties of the lipoprotein
subtractions. Visualization of focused lipoprotein is initially
achieved by soaking the agarose plate immediately after the run
in a precipitation reagent and viewing the gel against a dark
background and subsequently staining with sudan black. For the
HDL subtractions obtained by focusing the 1.073 gmL infranatant
at least ten bands can be clearly identified between pH 5.53 and
5.16 [58], However, isoelectric focusing required the prior
preparative ultracentrifugation of HDL and the multiple bands
obtained for each subtraction prevent the resolution of HDL2 and
HDL3.
All the above mentioned techniques require considerable
expertise and are relatively costly and time-consuming, and they
are practically not suitable for most clinical or
epidemiological studies. By 1982, the traditional methods of
separating HDL subfractions are still by means of analytical
ultracentrifugation and preparative ultracentrifugation, or
ultracentrifugation in an Airfuge [59].
1-3.8 Polyanion-divalent cation precipitation methods
For many years, the separation of HDL from LDL and VLDL
by precipitation has proved a very convenient method for clinical
and epidemiological investigations of these lipoprotein classes
[60]. At the end of the 70Ts, on the basis of studies by
Burstein and Scholnick [61], Gidez et al. [62] proposed a simple
and accurate method for the separation of the HDL2 and HDL
subtractions using a double precipitation with heparin-MnCl2 and
low molecular weight dextran sulfate (DS, MW 15,000). The
results of this technique correlate well with those obtained by
analytical and preparative ultracentrifugation. At low
concentrations of these reagents, Apo B containing lipoproteins
are precipitated from the serum. However, co-precipitation of HDL
occurs when the concentrations of the DS and MnCl2 are raised.
These observations suggested that there must be intermediate
concentrations of DS and MnCl2 between those at which it will not
precipitate HDL at all and those that at which it will
precipitate HDL maximally. Since the principle of the
precipitation methods are based on the ratio of protein to lipid
in the different lipoprotein subtractions. HDL2, which has a
lower protein to lipid ratio than HDL, would be expected to
precipitate under conditions that do not precipitate HDL. This
method has so far been applied to the determination of HDL2 and
HDL bound cholesterol in clinical and epidemiological studies. A
major drawback with the double precipitation method developed by
Gidez, is the positive interference of Mn+ with the cholesterol
determination by enzymatic methods currently used in most
laboratories, causing falsely elevated results [63]. On the other
hand, an attempt to use a chemical extraction method for the
determination of low HDL2-cholesterol concentration is imprecise.
Gidezs method became the method of choice for many
epidemiological studies for vears because of its simDlicitv.
A dramatic rise in the interest for the analysis of HDL
subfractions has occurred in the past few years since Gidez's
report. Several other commonly used precipitation reagents for
HDL have also been tried and developed. In 1984, Lundberg et
al.[64] described a method in which HDL is first separated from
VLDL and LDL with polyethylene glycol 6000 (PEG-6000). The
separation of HDL2 and HDL is then completed by precipitation
with dextran sulfate (MW 15,000) and MgCl2. The correlations
between results obtained by this method and by sequential and
density gradient ultracentrifugation have been reported as r=0.99
and 0.72, respectively. More recently, Talameh, Wei and Naito
[65], a study group from the Cleveland Clinic Foundation,
described another simple precipitation method for isolating
total HDL and its subfractions by two different concentrations of
2+
- Mg+ at constant dextran sulfate (MW 50,000) concentration. A
combined solution of DS and Mg2+ at respective final
concentrations of 0.9 gL and 27 mmolL was optimal for
separating total HDL from the other lipoproteins. The HDL
fraction was further resolved into HDL2 and HDL by addition of a
combined solution of a second DS and Mg2+ (10 gL and 1.5 mmolL)
to the total HDL supernatants. Fractions were measured for their
cholesterol content by enzymatic means. HDL2 and HDL measured by
this simple dual DS-MgCl2 method with an accuracy and precision
comparable to the well-established ultracentrifugation methods,
and yielded the correlation coefficients of 0.941 and 0.869 for
HDL2 and HDL, respectively.
Wiebe and Smith [66] have shown that the most commonly
used polyanion-divalent cation precipitation methods result in
different apparent levels of HDL-cholesterol. This may due to a
varying degree of coprecipatation of one or more HDL subfractions
with VLDL and LDL, leading to an altered composition of HDL
subfractions in the remaining supernatant. When the HDL2- and
HDL-cholesterol values obtained by different laboratories for
apparently healthy men and women are compared it becomes evident
that there are large differences between the reference ranges for
the HDL2 and HDL3 [671.
1.4 Aim of the present study
Premature atherosclerosis is an important risk factor
in renal disorders and a major factor limiting the survival of
uraemic patients under renal replacement therapy. For the
prevention of premature atherosclerosis, understanding and
A recent report indicates only the HDL2 has a protective action
against coronary heart disease. Seperation of the HDL
subtractions by ultracentrifugation methods is time-consuming,
expensive and not suitable for routine analysis. Double
precipitation methods have recently been described for separation
of the major HDL subtractions and quantitation of their
cholesterol content. Results obtained with the precipitation
technique correlated well with those obtained by preparative
ultracentrifugation and analytical ultracentrifugation and have
gained much popularity. In the present study, the dual
precipitation procedure described by Talameh et al. for isolating
total HDL and its subtractions has adapted so that the





Seventy-seven renal patients, 41 males and 36 females
at different stages of chronic renal failure were recruited from
the Aberdeen dialysis centre, Tung Wah Hospital and the Renal
Unit of Queen Mary Hospital, University of Hong Kong. They were
divided into three subgroups according to their stages and
treatments (Table 2).
2.1.1 Group I: Hemodialysis patients (HP)
Patients who were under maintenance hemodialysis twice
a week for 5 to 144 months were designated Group I. They
included 19 males and 12 females with mean+ SD ages of 40.3±
11.5 and 39.1+ 10.0 years, respectively. Serum urea and
creatinine concentrations in the pre-dialysis samples of this
group of patients were 40.8+ 7.2 mmolL and 1.55+ 0.24 mmolL,
respectively.
2.1.2 Group II: Continuous Ambulatory Peritoneal Dialysis
(CAPD) patients
The Group II (CAPD) patients included 10 males (age
43.7± 14.4 years) and 14 females (age 49.0+ 10.6 years) whose
peritoneal dialysis had been carried out with 2 litres of 1.5%
Dianeal solution exchanged three times daily via an indwelling
Tenckhoff catheter over 2 to 40 months. Patients were allowed
TABLE 2
Number of subjects and mean age in each group studied.































Abbreviations: Hemodialysis, HD; continuous ambulatory peritoneal
dialysis, CAPD; post renal transplantation, PRT.
liberal diets except that water intake was restricted to 500 mL
per day. Serum urea and creatinine concentrations in this group
of patients were 26.4+ 6.2 mmolL and 1.03± 0.24 mmolL,
respectively. Patients with diabetes mellitus, nephrotic syndrome
and hypothyroidism were all excluded from this study.
2.1.3 Group III: Post Renal Transplantation (PRT) patients
This group consisted of 12 males and 10 females who had
carried a renal graft for 4 to 49 months. Their mean+ SD ages
were 36.3± 10.8 and 31.3 ±8.9 years, respectively. Serum urea
and creatinine concentrations in this group of patients were 13.3
± 6.2 mmolL and 0.24+ 0.25 mmolL, respectively.
2.2 Control subjects
The control group for all the comparisons in this study
consisted of eighty apparently healthy medical and laboratory
staff and members of their families. This group included 40 males
and 40 females aged (mean+ SD) 29.6+ 10.4 and 31.1± 10.6
years, respectively.
2.3 Blood specimens
Blood was collected after a 12-16 hours overnight fast
whenever possible for all subjects included in this study.
Specimens were obtained prior to and immediately following the
hemodialysis for Group I (HD) patients. Usually, all the
biochemical tests were performed within five days; if not, the
serum samples were stored in sealed plastic tubes at -20 to -70°C
until determinations were carried out. All hypertriglyceridaemic
sera were properly diluted prior to the assay.
2.4 Methods
Lipid profiles were performed on all serum samples
Cholesterol and triglycerides were determined by enzymic methods
with Abbott a-gent reagents using the Abbott-VP (Abbott
Laboratories, South Passadena, CA 91030, USA). Cholestero]
concentrations in the HDL and HDL subtractions were measured bj
the method described by Talameh et al. [65] with some
modifications on the assay conditions. Apolipoprotein A-I (Ape
A-I) and Apolipoprotein B (Apo B) were measured by rate
nephelometry methods using the Beckman Apo-A1 and Apo-B kits in
the Beckman ICS Analyzer II system (Beckman Instruments, Inc.,
Fullerton, CA 92634, USA).
2.4.1 Dual precipitation method for HDL subfractionation
i. Reagents
- 2% dextran sulfate (DS). Five grams of dextran sulfate, (MW
50,000+ 5,000, Sochibo, SA, Boulogne, France) were dissolved in
deionized water containing 25 mg sodium azide, 250 mg gentamycin
sulfate, and 0.5 g chloramphenicol (Sigma Chemical Co., St.
Louis, MO 63178, USA); the pH and the final volume of the
solution were adjusted to 7.0 and 250 mL, respectively.
- 3.0 M MgCl2 solution. 60.963 g of magnesium chloride
(MgCl2.6H20, F.W. 203.3, Sigma Chemicals Co., St.Louis, MO 63178,
USA) was dissolved in deionized water and diluted to 100 mL. The
concentration of this solution was confirmed by atomic absorption
spectrophotometry.
- 0.6 M MgCl2 solution. The 3.0 M MgCl2 solution was
diluted 1: 5 with deionized water.
- Working DSMgCl2 solution A was prepared prior to use by
mixing equal volumes of the 2% dextran sulfate and 0.6 M MgCl2
solutions.
- Working DSMgCl2 solution B was prepared prior to use by
mixing equal volumes of the 2% dextran sulfate and 3.0 M MgCl2
solutions.
i. Fractionation of total HDL. One hundred uL of the working
DSMgCl2 solution A and 1.0 mL serum sample were mixed by
vortexing in a disposable polystyrene test tube (12 x 75 mm). The
mixture was allowed to stand at room temperature for 10 minutes,
then centrifuged at 1,500 x g for 15 min at room temperature. The
isolated clear supernatant was assayed for total HDL-cholesterol
and subjected to further fractionation.
ii. Precipitation of HDLo. Five hundred uL of the supernatant
containing the total HDL were mixed with 50 uL working DSMgCl2
solution B in a capped microfuge tube, kept at room temperature
for 20 min and then centrifuged at 9,500 x g for 5 min in a TDX
microcentrifuge (Abbott Laboratories, South Pasadena, CA 91030,
USA). The supernatants containing HDL were immediately removed
and analyzed for their cholesterol concentrations. The total HDL
and HDL-cholesterol concentrations were corrected for their
dilution factors of 1.10 and 1.21, respectively. The
concentration of the HDL-cholesterol was obtained by subtracting
the HDL-cholesterol from the total HDL-cholesterol.
2.4.2 Ultracentrifugation method for HDL subfrationation
The ultracentrifugation method described by Kirstein
and Carlson [67] was used for a validation study of the HDL
subfractions separated by the dual precipitation procedure.
Ultracentrifugation was carried out at a density of 1.125 gmL.
One mL of NaBr solution of density 1.3482 gmL (474 gL) was
added to 2 mL of serum in a polystyrene tube and mixed, 1 mL of
this serum preparation was transferred to an ultracentrifuge
tube, the tube was then overlaid with 1 mL of density 1.125 gmL
NaBr (168 gL) solution and ultracentrfugation was carried out
for 48 h at 10°C in a Beckman L-7500 ultracentrifuge using a Ti
40.3 rotor. The centrifugual force at average radius of the 40.3
rotor was 2.98 x 10 g min. All density salt solutions were made
in 0.001 M NaOH solution containing 0.1 gL of disodium-EDTA and
sodium azide. The densities were confirmed by a ZEISS
refractometer (ZEISS 0PT0N, Nr. 123073, Germany).
After ultracentrifugation the top layer containing the
density lower than 1.125 gmL lipoprotein concentrates was
removed by aspiration and the final volume of the bottom fraction
(HDL) was readjusted to the original volume (2 mL) with density
1.125 gmL NaBr solution. The HDL-cholesterol was measured and
corrected with the appropriate dilution factor.
Linear regression analysis and Student's t test for




Results are presented in two parts, the first part
consists of results from the experimental study of HDL
subfractionation while in the second part, results from the
observations of lipid abnormalities in renal patients are
summarized.
3.1 The experimental study of HDL subfractionation
3.1.1 Choice of specimens
i. Serum versus EDTA-plasma. For this purpose both EDTA-plasma
and serum samples prepared from freshly drawn human blood
specimens were analysed for HDL and its subtractions in the same
batch of run and results were compared. Table 3 outlines the mean
and+ SD values obtained from fifteen pairs of samples. The
EDTA-plasma had a greater HDL-cholesterol and lesser HDL2-
cholesterol mean values as compared to the serum sample results.
Figure 1 presents the effect of adding different volumes of
individual freshly pooled human serum to commercially prepared
5.0 mL size K2-EDTA (di-potassium EDTA, 7.5 mgvial, Sarstedt
Co., West Germany) bottles, mixing them and analysing for HDL and
its subtractions alongside with their neat( free of EDTA)
specimens. An in vitro demonstration of the interference of the
added EDTA with the dual precipitation method for the
determination of HDL2-cholesterol was obvious.
TABLE 3
























3 Results are expressed as mean+ SD, units in parentheses (n= 15).
p 0.001 (paired t-test)
A. EFFECT OF EDTA ON
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FIGURE 1. Effect of EDTA on the dual precipitation method for
HDL subfractionation.
ii- Serum versus heparinized-plasma. Fifteen pairs of serum and
heparinized-plasma prepared from another batch of freshly drawn
human blood specimens were again analysed for HDL and its
subtractions under same conditions as mentioned above. Results
are shown in Table 4. No significant difference in the mean
values of both HDL- and HDL2-cholesterol between the serum and
heparinized-plasma groups were observed. Moreover, added lithium
heparin appeared to have no effect on the precipitation of HDL2,
at least for the seven of the eight test samples (Figure 2).
3.1.2 Influence of the length of incubation time on the
precipitation of HDLo subfraction
A sufficient amount of an Apo B free HDL supernatant
was prepared by adding 1 volume of working DSMgCl2 reagent A to
10 volumes of a human serum pool. Aliquotes of the supernatant
were subsequently used for the HDL2 subfractionation. Figure 3
shows the influence of incubation time on the precipitation of
HDL2 subfraction as measured by delaying the time of incubation
at room temperature over a period of six hours before
centrifugation. A 20 to 30 min incubation period was needed for
optimal precipitation of the HDL2 subfraction. Further delay in
time over 90 min resulted in an increase in the precipitation of
the HDL2 as reflected by a decrease in the HDL-cholesterol
content in the final supernatant.
TABLE 4
























a Results are expressed as mean+ SD, units in parentheses (n= 15).
A. EFFECT OF HEPARIN ON
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FIGURE 3. Influence of the length of incubation time on the
precipitation of HDL2 subfraction.
3-1-3 Cholesterol level in the supernatant of total HDL as
a function of Mg— concentration
The concentration effect of the MgCl2 on the
precipitation of HDL and HDL subfractions was studied. As shown
in Figure 4, as the Mg+2 concentration was raised from about 5 to
227 mmolL at a constant dextran sulfate concentration of 0.9
gL, the cholesterol levels in the supernatant solutions
decreased from 3-3 to 0.8 mmolL, with less but much steadier
decreases after about 27 mmolL of Mg+2 concentration. In this
study, a final Mg+2 concentration of 161 mmolL was used for the
subsequent precipitation of HDL2. According to the report of
Talameh et al. [65], dextran sulfate (MW 50,000) in the
concentration range of 0.45 to 1.37 gL had no effect on HDL
cholesterol levels. If EDTA plasma samples are used, slightly
higher total HDL-cholesterol and lower HDL2-cholesterol values
will be obtained because of incomplete precipitation of the Apo B
containing lipoproteins due to a decrease in the effective Mg+2
concentration in the presence of the chelating agent- EDTA.
3.1.4 Effect of storage of serum on concentration of
cholesterol in total HDL and HDL subfractions
For some of the patient serum specimens in this study,
it was necessary to store serum samples until analyses could be
conveniently carried out. This exercise was designed to determine
the effect of storage temperatures on the precipitation procedure
for the HDL subfractionation. Khan and Elkeles [691 studied the
effects of storage conditions, freezing and thawing on HDL
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FIGURE 4• Cholesterol level in the supernatant of total HDL
as a function of Mg+2 concentration.
(MW 15,000) precipitation, and reported that samples for total
HDL-, HDL- and HDL2-cholesterol determinations should be assayed
within 2 days if stored at 4°C. If stored at -20°C, the samples
should be assayed within one month. In Table 5 the results of the
storage trial at refrigerator (2-8°C), freezer (-20°C) and deep
freeze (-70°C) temperatures for the 10 individual freshly pooled
human serum preparations over 3 months show that samples for
total HDL and HDL subfractionation should be assayed within 5
days of receipt if stored at 2-8°C, as both total HDL- and HDL2-
cholesterol levels may decrease thereafter. When frozed at
either -20°C or -70°C specimens may be kept up to 3 months or may
be longer. Some validation of the storage effect at refrigerator
temperature using freshly drawn male human serum sample had been
attempted. Figures 5 and 6 show there were small changes in the
distribution of HDL subfractions for the human serum sample after
day 5 but not for the commercial control serum preparation,
probably due to the preservatives that had been added by the
manufacturer.
3.1.5 Precision
The degree of within-run and between-run imprecision
for the two levels of commercial control serum preparations are
summarized in Table 6. These results are based on the analysis of
13 estimations of total HDL- ,HDL- and HDL2-cholesterol in the
same run for within-run imprecision, and for between-run
variation, on 89 sets of analyses on freshly reconstituted
control serum preparations over a period of 5 months. All data
TABLE 5
Effects of storage temperatures on HDL-, HDLo- and HDLp-cholesterol measurements by the precipitation method.
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Figure 5. Distribution of HDL subtractions for serum specimen
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Figure 6. Distribution of HDL subtractions for control serum
stored at refrigerator temperature, 2-8°C.
TABLE 6


















































was used for statistical calculations. Since the mean difference
in the plasma HDL-cholesterol concentration between subjects
confronted with coronary artery disease and apparently healthy
subjects in the Framingham studies [68] was about 0.25 mmolL
(10 mgdL), the importance of ensuring that the HDL-cholesterol
method is highly precise is apparent. It has been suggested that
the minimum precision for these methods should be less than 0.10
mmolL (4 mgdL) for within-run and between-run variations. In
this study, the HDL2-cholesterol gave the largest relative
variation. However, the absolute variations (as reflected by the
+SD values) of both HDL2- and HDL-cholesterol were nevertheless,
similar( SD 0.06 mmolL).
3-1.6 Validation of the precipitation method
i. Accuracy of total HDL fractionation. The accuracy of the
present method using dextran sulfateMgC for total HDL was
evaluated by a comparison study with a well-established
phosphotungstic acidMgC (PTA) procedure currently employed by
our laboratory [70]. The method has been standardised using
control serum preparations obtained from the Australian Lipid
Standardisation Programme (ALSP). Fourty-four individual patient
serum samples were analysed by the DSMgC and the PTA methods.
The results are schematically summarized in Figure 7.
ii. Accuracy of HDLo subfractionation. The accuracy of the
method was assessed using 16 individual freshly pooled human
serum samples. Results comparing HDL-cholesterol concentrations
obtained by preparative ultracentrifugation and dual
precipitation are presented in Table 7. Values obtained using the




































Phosphotungstic acid Mg method
Figure 7. Regression analysis of cholesterol content in total HDL determined by
dextran sulfate Mg+2 method and phosphotungstic acid Mg+2 method.
TABLE 7
Data comparison on cholesterol content of HDL subfraction in pooled sera separated by preparative ultracentrifugation

















16 0.02+ 0.020 0.8?± 0.008 -5.4 0.988
Percent difference of mean values of the precipitation and the preparative ultracentrifugation methods divided by the
mean value of the preparative ultracentrifugaton method.
dual precipitation method generally agree well with those
obtained by preparative ultracentrifugation. These results were
obtained over a range of HDL- cholesterol values (0.40-1.00
mmolL), as determined by the ultracentrifugation reference
method. The mean value of HDL- cholesterol measured by
precipitation was lower by 5.4%. Individual results for HDL-
cholesterol concentration are schematically summarized in Figure
8. The within-run precision of the ultracentrifugation and the
precipitation procedures for this purpose were assessed by
running 8 replicate assays of HDL-cholesterol in a pool of
normal human serum by both methods. The coefficients of variation
were 3.2 and 0.9%, at a mean concentration of 0.92 and 0.87
mmolL, respectively for the two methods. Appropriate experiments
indicated that the presence of NaBr in the ultracentrifugally
prepared lipoprotein fraction did not interfere with the
enzymatic cholesterol measurement.
3.1.7 Effect of dilution on hypertriglyceridaemic serum
The effect of dilution was assessed by diluting a serum
sample in the presence of significant amount of triglycerides
(4.5 mmolL). Table 8 outlines the values obtained on the four
levels of dilution ratios, using 0.85% NaCl as diluent. The
results show that there is no apparent change in the total HDL-
and HDL-cholesterol levels after corrected for the appropriate
dilutions. The percent differences ranged from 0-2.6% and 0.6-
7.5% for total HDL-cholesterol and HDL-cholesterol,
respectively.
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Ultracentrifugation method
Figure 8. Regression analysis of cholesterol content in HDL determined
by dual precipitation method and ultracentrifugation method.
TABLE 8
Effect of dilution on HDL subfractionation (parallelism)3.
Dilution HDL-cholesterol HDL-cholesterol ffi-cholesterol

































a All dilutions were made in 0.85% NaCl, assayed in duplicate.
b Cholesterol content after corrected for appropriate dilution.
c Percent difference as compared with the respective undiluted
fraction.
3-2 Serum lipid, lipoprotein and apolipoprotein concentrations
in normal control subjects and renal patients (Table 9)
Distribution of serum triglycerides (TG), cholesterol
(TC), total HDL-cholesterol (HDL), cholesterol content in HDL2
(HDL2), apolipoprotein A-I (Apo A-I) and apolipoprotein B (Apo B)
in male and female patients as compared to control subjects of
each sex (all ages) are schematically shown in Figures 9 and 10.
3.2.1 Results for normal control subjects (Table 10)
For the total population of each sex (all ages),
concentrations of cholesterol, total HDL-cholesterol and HDL2-
cholesterol were lower in males than in females. The differences
between males and females in the mean concentrations of total
HDL- and HDL2~cholesterol in the same 19-30 year old age-group as
well as the over 30 years of age groups were also significant.
3.2.2 Results for Group I (HP) patients (Table 11)
As expected, the hemodialysis patients had
significantly higher mean serum triglyceride concentrations than
their same age groups for both males and females. Mean
concentrations of cholesterol, HDL- and HDL2-cholesterol, Apo A-I
and Apo B were all significantly reduced in both males and
females of this group. No significant difference in the HDL-
cholesterol was observed between the males and females implies
that a more pronounced reduction of lipoprotein of this class in
females than males in this group.
TABLE 9
Serum lipid, lipoprotein and apolipoprotein concentrations
in control subjects and in patients treated with
hemodialysis, CAPD, and renal transplantation (mean+ SD)
Sex n Age TG TC HDL HDL HDL2 Apo A-I Apo B
mean+ SD mmolL mmolL mmolL mmolL mmolL gL gL
Controls H HO 29.6+10.1 1.02+ 0.33 11.1+ 0.8 1.68+ 0.36 1 1.08+ 0.18 0.60+ 0.25 11 1.51 ±0.26 0.61 ±0.16
F 10 31.1+10.6 0.91+0.31 1.6+0.6 1.87+0.31 1.11+0.16 0.76+0.30 1.62+0.21 0.69+0.11
Total 80 30.3± 10.5 0.98+ 0.31 1.3+ 0.8 1.78+ 0.31 1.09± 0.17 0.68+ 0.29 1.58+ 0.21 0.67 ±0.11
HD H 19 10.3+ 11.5 1.57+ 0.78 3-8+ 1.1 1.27+ 0.350.82+ 0.20 0.11+ 0.27 1.19± 0.23 0.61+0.18'
F 12 39.1+ 10.0 1.67± 0.61' 1.0+ 0.8 w 1.27+ 0.35 0.79+ 0.17 0.18+ 0.29 1.19+ 0.25' 0.61± 0.13
Total 31 39.8+ 11.0 1.61+ 0.72 3.9± 1.0 1.27+ 0.35 0.81+ 0.19 0.16+ 0.28 1.19 ±0.21 0.62 ±0.16
CAPD M 10 13.7± 11.1 3.76± 2.05 6.1± 1.2 0.80± 0.17W 0.60± 0.15 0.20+ 0.11%% 1.12± 0.32 0.99± 0.25
F 11 19.0± 10.6 2.59± 1.16 6.8+ 1.8 1.07± 0.30 0.70+ 0.25 0.37 ±0.19 11 1.73 ±0.32 1.19±0.25t
Total 21 16.8+ 12.6 3.07± 1.69 6.1± 1.5 0.95± 0.28 0.65± 0.21 0.29 ±0.18 1.60 ±0.36 1.10 ±0.27
PIT H 12 36.3± 10.8 3.10+ 1.26 6.2 ±1.l 1.11± 0.38 0.97± 0.30 0.11+ 0.25 1.12 ±0.37 1.17± 0.51
F 10 31.3± 8.9 1.99± 0.81 5.8+ 0.9 1.76+ 0.53 1.00+ 0.19 0.76± 0.11 1.51 ±0.32 0.90± 0.21
Total 22 31.0± 10.3 2.60+ 1.21 6.0 ±1.2 1.57± 0.19 0.98± 0.26 0.58+ 0.39 1.17± 0.35 1.05 ±0.15
Abbreviations: Hemodialysis, IID; continuous ambulatory peritoneal dialysis, CAPD; p03t-renal transplantation, PRT; triglycerides, TG; cholesterol,
TC; total IIDL-cholesterol, HDL; IIDL-cholesterol, IIDL; IIDL2-cholesterol, HDL2; apolipoprotein A-I, Apo A-I; apolipoprotein B, Apo B.
p 0.05 vs HD
• p 0.01 vs IID
» p 0.001 vs IID
II p 0.05 vs CAPD
IBp 0.01 vs CAPD
BUB p 0.001 vs CAPD
XX p 0.01 va PRT
XXX p 0.001 va PRT
I p 0.05 vs female

































































N H C P
Figure 9. Distribution of serum lipid, lipoprotein and
apolipoprotein concentrations in male uraemic patients and
normal control subjects
Abb rev i 31 ions; Triglycerides, TG, cholesterol, TC; total HDL-
cholesterol, HDL; HDL2-cholesterol, HDL2; apolipoprotein A-I, Apo A-I;
apolipoprotein 8, Apo 3; normal control subjects, N; hemodialysis
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Figure 10. Distribution of serum lipid, lipoprotein and
apolipoprotein concentrations in female uraemic patients
and normal control subjects
Abbreviations: Triglycerides, TG; cholesterol, TC; total HDL-
cholesterol, HDL; HDL2-cholesterol, HDL2; apolipoprotein A-I, Apo A-I;
apolipoprotein B, Apo 3; normal control subjects, N; hemodialysis
patients, H; CAPDpatients, C; PRT patients, P.
TABLE 10
Serum lipid, lipoprotein and apolipoprotein concentrations
in control subjects of specific age groups for both sexes (mean+ SD)
Age
group
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1.70+ 0.36
1 do i n v
1.09+ 0.18
1 nA. n 11











1.11+ 0.19 0.59+ 0.23
-.r.
1.51± 0.29 0.72+ 0.15
Abbreviations: Triglycerides, TG; cholesterol, TC; total HDL-cholesterol, HDL; HDL-cholesterol, HDL; HDL2~cholesterol, HDL2; apolipoprotein A-I,
Apo A-I; apolipoprotein B, Apo B.
p 0.05
TABLE 11
Serum lipid, lipoprotein and apolipoprotein concentrations
in control subjects and in patients treated with
hemodialysis- matched with sex and age-group (mean+ SD)
Sex n Age TG TC HDL HDL3 HDL2 Apo A-I Apo B







'10.3+ 7.1 1.06+ 0.33 '1.6+ 0.8 1.65+ 0.31 1.11+0.19 0.51+ 0.23 1.51+ 0.21 0.72+ 0.15







39.2+ 9.6 0.97+0.31 1.8+0.8 1.88+0.32 1.16+0.20 0.72+0.29 1.61+0.19 0.72+0.12
39.1+ 10.0 1.67+ 0.61 1.0+ 0.8 1.27± 0.35 0.79+ 0.17 0.18+ 0.29 1.19 ±0.25 0.61 +0.13
Abbreviations: Hemodialysis, HD; triglycerides, TG; cholesterol, TC; total HDL-cholesterol, HDL; HDL-cholesterol, HDL3; HDL2-oholesterol, HDL2;




3.2.3 Results for Group II (CAPD) patients (Table 12)
Mean serum triglyceride, cholesterol and Apo B
concentrations were significantly higher than in either the
control subjects or Group I (HD) patients for both sexes. This
group also had significantly lower mean serum HDL- and HDL2-
cholesterol concentrations than the controls and HD patients. The
mean HDL2-cholesterol concentrations in male and female patients
were significantly reduced to lower than half of the mean values
of their control subjects. The mean serum Apo A-I concentration
of female patients was close to that of controls and the
difference in males was not significant.
3.2.4 Results for Group III (PRT) patients (Table 13)
Mean serum triglyceride, cholesterol and Apo B
concentrations were significantly higher than in either the
control subjects or Group I (HD) patients for both sexes. In
comparison with controls, no significant abnormalities in Apo A-I
and HDL-cholesterol values could be found. The male patients had
a slightly reduced mean serum concentration of HDL2-cholesterol
as compared to the control subjects of the same age group; this
reduction of HDL2-cholesterol was not observed in the female
patients.
3.2.5 Comparison of serum lipid, lipoprotein and
apolipoprotein concentrations in Group I (HD)
patients before and after the hemodialysis
TABLE 12
Serum lipid, lipoprotein and apolipoprotein concentrations
in control subjects and in patients treated with CAPD-























'12.2+ 5.2 1.11+ 0.38 4.6+ 1.0 1.62+ 0.26 1.11+ 0.20 0.51+ 0.19 1.51+ 0.18 0.72+ 0.18







48.1+ 8.9 1.07+0.40 5.4+0.7 2.01+0.33 1.22+0.23 0.79+0.34 1.72+0.16 0.77+0.13
49.0+ 10.6 2.59+ 1.16 6.8+ 1.8 1.07+ 0.30 0.70+ 0.25 0.37± 0.19 1.73+ 0.32 1.19+ 0.25
Abbreviations: Continuous ambulatory peritoneal dialysis, CAPD; triglycerides, TG; cholesterol, TC; total HDL-cholesterol, HDL; HDL-cholesterol,





Serum lipid, lipoprotein and apolipoprotein concentrations
in control subjects and in patients treated with renal




























































Abbreviations: Post-renal transplantation, PRT; triglycerides, TG; cholesterol, TC; total HDL-cholesterol, HDL; HDL-cholesterol, HDL;
HDI-cholesterol, HDL2; apolipoprotein A-I, Apo A-I; apolipoprotein B, Apo B.
» p 0.001
Table 14 summarized the results of serum lipid,
lipoprotein and apolipoprotein concentrations (mean+ SD) of
Group I patients prior to and immediately after maintenance
hemodialysis. The mean serum triglyceride concentration was
significantly decreased while the mean serum concentrations of
HDL- and HDL2- cholesterol were significantly increased after the
5-hour hemodialysis period. A significant higher mean serum
cholesterol concentration was observed in male but not in female
patients immediately following the hemodialysis. No significant
difference in mean serum concentrations of Apo A-I and Apo B
could be found.
TADLE VI
Serum lipid, lipoprotein and apolipoprotein concentrations
in patients treated with hemodialysis- comparison of



















































Abbreviations: Triglycerides, TG; cholesterol, TC; total IIDL-chole3terol, HDL; i-cholesterol, HDL3; HDL2-cholesterol, HDL2; apolipoprotein A-I,







Currently available procedures for separating the two
major high density lipoprotein subfractions, HDL2 and HDL are
time consuming and for the most part, require sophisticated
ultracentrifugal techniques and are not very suitable for
routine measurement of HDL subfractions. Although the specific
mechanisms of lipoprotein precipitation by polyanions and
divalent cations have not been established with certainty, the
good agreement of HDL2- and HDL-cholesterol values with those
obtained by ultracentrifugation methods and the simplicity of the
procedure have made this technique more suitable for clinical and
epidemiological study. The principle of the presently applied
dual precipitation method is based on the fact that, the larger,
lipid-rich lipoproteins, VLDL and LDL, form insoluble complexes
more readily than do the smaller, protein-rich HDL in the
presence of polyanions and divalent cations. The extent of
protein coprecipitation is a function of the method and
conditions of precipitation. On the other hand, the HDL2, which
has a lower protein-lipid ratio than HDL, would be expected to
precipitate under conditions that do not precipitate HDL.
Cholesterol remaining in the two subsequent supernatant solutions
can be considered to represent HDL, and HDL.
Results obtained from the effect of EDTA on the
fractionation of HDL and its subfractions has shown that although
for years it has been suggested that EDTA can prevent auto-
oxidation of certain lipoproteins after the blood specimens are
drawn [713, the use of EDTA-plasma in precipitation methods for
determination of HDL and its subfractions cannot be recommended
because of the imcomplete precipitation of the Apo B containing
lipoproteins due to a decrease in the effective Mg+2
concentration in the presence of the chelating agent- EDTA.
These problems can be overcome by doubling the concentration of
the divalent cation [72], The precipitation method is still
sensitive for serumplasma differences unless each specimen
received for HDL subfractionation contains the same amount of
EDTA, and practically, it is not easy to control [731.
It has been proposed that HDL is converted into HDL2 by
uptake of surface components from triglyceride-rich lipoproteins
when their triglyceride moiety is hydrolyzed by lipoprotein
lipase. In this conversion lecithin-cholesterol acyltransferase
may be involved [333. The reverse process, namely the conversion
of HDL2 into HDL seems to be mediated by hepatic lipase [353.
Nevertheless, such enzyme mediated interconversion might be
retarded by freezing. Results obtained from the effect of storage
at different temperatures indicate that samples to be used for
HDL subfractionation may be stored at 2-8°C or less and that
analyses should be carried out as soon as possible. Recently,
Khan and Elkeles [69] reported that samples for total HDL-,
HDL2- and HDL-cholesterol, using heparin manganesedextran
sulfate precipitation should be assayed within 2 days if stored
at 4°C. If stored at -20°C, the samples should be assayed within
one month, preferably within 14 days. Franceschini et al. [74]
using rate zonal ultracentrifugation, reported that the HDL2
concentration and composition do not change during prolonged
storage at 4°C, but the HDL subtraction is markedly modified.
Total lipoprotein mass is reduced, flotation rate is decreased,
and the lipid composition is significantly altered; these changes
could be prevented by the addition of high concentrations of salt
before storage. Bachorik et al.[75] reported that changes in
HDL-cholesterol are minimized if heparin-Mn+ supernatants,
rather than unfractionated plasma, are stored at -70°C. The
effect of such storage of total HDL supernatants on HDL
subfraction determinations remains to be elucidated.
In the validation procedure for the determination of
the cholesterol content of the HDL subtractions, one preparative
ultracentrifugation at density 1.125 gmL was used to obtain HDL
and phosphotungstic acidMg1 precipitation to obtain total HDL.
The reason for choosing this single ultracentrifugation procedure
is that stepwise preparative ultracentrifugation requires
repeated ultracentrifugation, density readjustment and long
exposure of these lipoproteins to high salt concentrations and
high gravity fields. These treatments have been reported to
result in interference with lipid-protein binding. There are only
minuscule amounts of other lipoproteins besides HDL with a
density greater than 1.125. In addition, the extra step of
adjusting the solution with a density of 1.125 to 1.210 causes
greater errors than directly analyses of the fraction with a
density greater than 1.125.
The precision study for the HDL subfractionation by the
precipitation method shows large relative variation. However, the
absolute variations (as reflected by the+ SD values) of both
HDL2- and HDL-cholesterol are nevertheless small (SD 0.06
mmolL), which are sensitive enough for detecting those samples
with low levels of HDL2.
In summary, the simple dextran sulfate-Mg+2 dual
precipitation method used in this study measured total HDL and
its subfractions with accuracy and precision comparable with the
widely used phosphotungstic acid-Mg+2 and ultracentrifugation
methods, respectively. The method seems applicable to evaluation
of HDL2- and HDL-cholesterol concentrations in clinical and
epidemiological studies.
4.2 Reference values
Control subjects for this study were from a relatively
small population of both sexes, and comprised of 40 males and 40
females. Mean ages for the two sex groups were quite similar,
being 29.6+ 10.4 years for males and 31.1+ 10.6 years for
females. As pointed out by Henry [76],— the establishment of
normals is further complicated by many variables including sex,
age, race, climate, season, diet, time of day, day to day
variation, menstrual cycle or whether or not the individual is in
the post-absorptive state. For the purpose of this study,
the reference values are applicable only for the evaluation of
the patients laboratory test results for certain lipid profiles.
As a standard comparison, the reference ranges are derived from
the respective subpopulation closely matched to the patient for
age and sex.
To evaluate the possible sex-related differences of the
serum lipid profile results, a subpopulation of healthy control
subjects consisting of 20 males and 20 females aged 19—30 years
with mean(+ SD) ages of 22.2(+ 2.7) years and 23.2(+ 3.2)
years respectively, was used. To the best of the information in
hand, none of the female controls were taking oral
contraceptives. Mean concentrations of serum cholesterol, total
HDL- and HDL2-cholesterol were significantly higher in females
than males of the same 19-30 year age-group as well as the over
30 years of age groups. Mean concentrations of serum Apo A-I and
Apo B appeared higher while triglyceride was lower in females but
differences were not statistically significant. The large
difference in HDL concentration between males and females in many
communities has been reported [77, 78] but whether this
difference is related to the subtraction concentrations is still
controversial [791. In this study, values of total HDL-, HDL2-
and HDL-cholesterol for both male and female control subjects
were similar to the reference ranges found by Kirstein and
Carlson [67] and higher than those reported by Gidez et al [62].
However, results from Table 10 of this report suggests that the
biases of age and sex and HDL2-subfraction cholesterol levels
should be taken into consideration in subsequent analysis of
patients results.
4.3 Discussion on results of Group-I (HP) renal patients
Cardiovascular disease is one of the most frequent and
serious complications in patients with chronic renal failure
receiving maintenance hemodialysis although whether
atherosclerosis is actually accelerated in these patients is
still controversial [16, 17]. Reports from the United States and
Europe indicate a high incidence of cardiovascular deaths in
hemodialysis patients being 46.9% and 48.2%, respectively, while
in non-uraemic age-matched groups cardiovascular death would
account for 13.6% of all cases [80]. All patients on
hemodialysis have a similar underlying metabolic disturbance and
it is not clear why only a proportion of them exhibit
dyslipoproteinaemia. The present study confirms previously well-
known lipid abnormalities in chronic renal failure patients
treated with hemodialysis, i.e., hypertriglyceridaemia, a
decrease of serum HDL-cholesterol. As already shown in Table 11,
serum triglyceride concentration was significantly elevated in
both male and female patients while cholesterol, HDL- and HDL2-
cholesterol were significantly decreased. No difference was
observed in the mean concentration of HDL-cholesterol between
male and female patients of this group.
There are several reports to suggest that Apo A-I may
be the critical factor necessary for the uptake of free
cholesterol from cell membranes by the HDL particle [81, 82] and
patients with Apo A-I deficiency developed severe atherosclerosis
[83]. In uraemic patients receiving hemodialysis, Brunzell et
al.[84] had reported that they showed normal Apo A-I levels, but
a recent study by Goldberg et al. [19] showed that patients
having a risk for cardiovascular disorders had lower plasma
levels of Apo A-I, they also demonstrated by ultracentrifugation
separation that such patients, had decreased HDL2 levels. As for
Apo A-I, the results of the present study indicate that in Group
I (HD) patients the levels were significantly decreased in both
males and females, and since the content of Apo A-I is higher in
HDL2 than in HDL, so the low levels of HDL-cholesterol might be
responsible for the increase risk of the developement of vascular
disease. From this point of view, one could believe that lipid
abnormalities were partly contributing to coronary heart disease
in patients with chronic renal failure. The studies on
apolipoproteins and the HDL subtractions in patients undergoing
hemodialysis therapy might provide a clue to identifying the
patients having a risk for coronary heart disease although there
are some doubts about whether the HDL2 subtraction is actually
important. A long-term study on these patients following their
course of treatment is needed to clarify an association between
the above lipid abnormalities and cardiovascular disorders.
4.4 Discussion on results of Group II (CAPD) renal patients
Since its first introduction in 1976 by Popovich and
colleagues [85] Continuous Ambulatory Peritoneal Dialysis (CAPD)
has gained increased acceptance as a primary form of dialysis
treatment in the mangement of patients with end stage renal
failure. In treating patients with chronic renal failure by CAPD,
it is at present customary to use dialysis fluids containing
glucose as the major osmotic agent, the usual concentrations
being 15 gL (1.5%) and 42.5 gL (4.25%). Such patients are
therefore subject to a glucose load due to absorption from the
dialysate and this loading will be virtually continuous. Since
impaired glucose tolerance is often observed in uraemic patients
[86], it is of no surprise that hypertriglyceridaemia may result
in the impairment of glucose tolerance in these patients treated
with CAPD. This constant supply of glucose may not be subject to
the same regulation as that provided by the oral route [87]. The
continual glucose absorption may lead to continuous stimulation
of the pancreatic beta-cell and a consequent depletion of these
cells.
The results of this study confirm that the triglyceride
levels are elevated in patients with CAPD as compared with both
the control group and the hemodialysis group. Reports from
several centres [88] suggest that CAPD is accompanied by a
further increase in the hypertriglyceridaemia of renal failure.
The dialysis does not correct the lipid abnormalities and may
even make them worse. However, published studies of lipid during
CAPD treatment show contradictory results. Roncari et aL [89]
found a elevation of HDL-cholesterol over 3-6 months whereas
Cantaluppi et al. [90] noted a slight fall over 12 months. The
present study of lipid metabolism in a group of Chinese patients
on three 2-L exchanges of CAPD has found that the CAPD patients
had mild hypertriglyceridaemia, and the mean HDL- and HDL2-
subfraction cholesterol were significantly reduced in males and
in females. Insofar as lipids and apolipoproteins are supposed to
be involved in the atherosclerotic process, high levels of
cholesterol and Apo B and low levels of HDL- and HDL2~cholesterol
in this group of patients treated with CAPD could account for
their high risk of developing coronary heart disease.
4-5 Discussion on results of Group III (PRT) renal patients
Hypertriglyceridaemia and hypercholesterolaemia
following renal transplantation have already been reported in
Western countries [13, 14] and were also observed in the present
study on Chinese patients. A possible role of the corticosteriod
andor immunosuppressive therapy in the increase in triglycerides
and cholesterol cannot be excluded. Serum HDL-cholesterol was
reported to be normal [91, 92], decreased [93] or even increased
[94, 95] in several studies. In these reports, no distinction
was made between results from male or female transplant patients.
Serum Apo A-I concentration was reported to be normal [92] or
increased [91,94,]. It has been found that the renal transplant
patients in this study show slightly decreased but normal mean
HDL-cholesterol and Apo A-I levels in both males and females. The
mean concentration of ffl-cholesterol was slightly decreased in
male but not in female patients as compared to their respective
age-matched control groups. The fact that no difference in the
mean concentration of HDL2~cholesterol between the hemodialysis
group and the post renal transplantation group was observed may
indicate that male patients are more susceptible to the
accelerated development of atherosclerosis if the so called
lipid hypothesis [96] is true.
4.6 Discussion on comparison results of pre- and post-dialysis
It is well known that at least two triglyceride lipases
are released into the circulation by heparin [97]. One of these
enzymes is identical to adipose tissue lipoprotein lipase (LPL),
whereas the other resembles the hepatic lipase (HL). The role of
LPL in the catabolism of triglycerides is well-documented [98].
Plasma HDL- and HDL2-cholesterol concentrations have also been
shown to correlate positively with postheparin plasma LPL
activity [33? 98], HL is a heparin-releasable lipolytic enzyme
present in the sinusoidal endothelium of the liver, it is a key
enzyme in the degradation of HDL2 lipid esters, it causes
selective hydrolysis of HDL2-phospholipids and concomitantly
uptake of its cholesterol esters in the liver.
Kuusi et al. [99] gave the first evidence for a role
of HL in the metabolism of HDL in human; an inverse correlation
was demonstrated between postheparin HL activity (PHLA) and
plasma HDL2-cholesterol. It is remarkable that a correponding
relationship could not be found between PHLA and HDL which
strongly suggests that HL is highly selective and hydrolyzes only
the HDL2 subfraction. Thus the HL could participate in the
regulation of plasma total HDL level by influencing the HDL2,
which is actually known to be the physiologically variable
component of HDL. Postheparin HL and LPL activities had been
reported to be reduced in patients treated with hemodialysis and
CAPD [100, 101]. The reason for low PHLA in patients receiving
heomdialysis remains speculative, the presence of an undialysable
uraemic toxin and exhaustion of the enzyme stores after repeated
heparin administration in dialysis have been suggested as
possible explanations for the lipid abnormalities found in these
uraemic subjects. So, long exposure of those patients receiving
hemodialysis twice weekly to high dose of heparin may cause a
decrease in the circulating levels of HDL and HDL2 as reflected
by decreases in their cholesterol content.
However, several observations argue against the
possibility that the low postheparin plasma HL levels in the
hemodialysis patients are due to repeated heparinization. First,
it has been shown that the activity of both enzymes returns to
normal within 48 hours after the end of the hemodialysis.
Furthermore, injection of heparin into normal volunteers at 48-
hour intervals did not influence the activity of the enzymes
C102].
In this study, attention was focused on the independent
relationship of HDL subfractions and other serum lipid
concentrations between pre- and post-dialysis. The post-dialysis
HDL- and HDL2-cholesterol were increased and the triglyceride
concentration was decreased. There is still a lack of
understanding of how hemodialysis affects this phenomenon.
Further studies are clearly needed to elucidate the relation
between lipoprotein levels, especially the HDL2 subtraction and
postheparin plasma lipase activities in chronic uraemic patients
treated with hemodialysis.
In conclusion, the results of this study indicate that
uraemic patients receiving renal replacement therapy have many
abnormalities in apolipoproteins and lipids. Most of the
described changes, including hypertriglyceridaemia and low total
HDL- and HDL2-cholesterol are thought to predispose to atheroma
which is a major cause of death in renal failure. These
abnormalies are similar to those found in non-uraemic subjects
who may have a risk for coronary vascular disease. Although the
kidneys appear to be involved in HDL metabolism, the mechanism
involved, and the impact on circulating levels of plasma
lipoprotein remain unknown and whether the decreased serum total
HDL- and HDL2~cholesterol is the cause or the consequence of the
decreased LPL activity is still uncertain. However, it is
possible that low serum HDL2-cholesterol together with the
hypertriglyceridaemia represents a decrease in the anti¬
atherogenic defence of the organism rather than an increased
atherogenic potential.
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